<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03263273</url>
  </required_header>
  <id_info>
    <org_study_id>HY01-003</org_study_id>
    <nct_id>NCT03263273</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Topical Minocycline Gel in Patients With Papulopustular Rosacea</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of 1% and 3% Topical MIinocycline Gel (HY01) in Patients With Papulopustular Rosacea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hovione Scientia Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hovione Scientia Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of once-daily application of 1% and 3% HY01 Topical Gel, as assessed
      by the change in inflammatory lesion count from baseline over the 12-week treatment period in
      patients with moderate-to-severe papulopustular rosacea.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Anticipated">September 28, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 28, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Lesion Count</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate the efficacy of once-daily application of 1% and 3% HY01 Topical Gel, as assessed by the change in inflammatory lesion count from baseline in patients with moderate-to-severe papulopustular rosacea</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Assessment (IGA) Score</measure>
    <time_frame>12 weeks</time_frame>
    <description>Evaluate the efficacy of once-daily application of 1% and 3% HY01 Topical Gel, in improving the Investigator's Global Assessment (IGA) scores from baseline over the 12-week treatment period in patients with moderate-to-severe papulopustular rosacea as defined as either a 2 point improvement from baseline or an improvement to &quot;clear&quot; or &quot;almost clear&quot; on the IGA</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">249</enrollment>
  <condition>Rosacea</condition>
  <condition>Papulopustular Rosacea</condition>
  <arm_group>
    <arm_group_label>Topical Vehicle Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical administration of vehicle gel. Regimen: Apply once daily, at bedtime to the face</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1% Topical Minocycline Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical administration of 1% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3% Topical Minocycline Gel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical administration of 3% Topical Minocycline Gel. Regimen: Apply once daily, at bedtime to the face</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1% Topical Minocycline Gel</intervention_name>
    <description>Compare the safety and efficacy of three treatment regimens: 1% topical minocycline gel, 3% topical minocycline gel &amp; topical gel vehicle</description>
    <arm_group_label>1% Topical Minocycline Gel</arm_group_label>
    <other_name>HY01 Topical Gel, 1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3% Topical Minocycline Gel</intervention_name>
    <description>Compare the safety and efficacy of three treatment regimens: 1% topical minocycline gel, 3% topical minocycline gel &amp; topical gel vehicle</description>
    <arm_group_label>3% Topical Minocycline Gel</arm_group_label>
    <other_name>HY01 Topical Gel, 3%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Topical Vehicle Gel</intervention_name>
    <description>Compare the safety and efficacy of three treatment regimens: 1% topical minocycline gel, 3% topical minocycline gel &amp; topical gel vehicle</description>
    <arm_group_label>Topical Vehicle Gel</arm_group_label>
    <other_name>HY01 Topical Gel, 0%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who had provided written informed consent to participate in the study.

          -  Male or non-pregnant female aged ≥ 18 years with a clinical diagnosis of moderate to
             severe facial rosacea, defined as the presence of: i. At least twelve and not more
             than forty inflammatory facial lesions (i.e., papules/pustules), AND ii. Subjects with
             a grade 3 or 4 on the 5-point Investigators Global Assessment (IGA) scale, AND iii.
             Persistent facial erythema (scored as at least mild on Erythema Severity Scale), AND
             iv. Facial telangiectasia (scored as at least mild on Telangiectasia Severity Scale.

          -  Subject willing to minimize external factors that might trigger rosacea flare-ups as
             recommended per protocol and patient instructional guide (e.g., spicy foods, thermally
             hot foods and drinks, hot environments, prolonged sun exposure, strong winds and
             alcoholic beverages).

          -  Non-nursing, female subjects of child bearing potential, who are using an acceptable
             form of birth control: total abstinence, oral (birth control pills), intravaginal:
             (e.g. NuvaRing®), implantable (e.g. Norplant®), injectable (e.g. Depo-Provera®) or
             transdermal (e.g. Ortho Evra®) contraception; intrauterine device (IUD);
             double-barrier (diaphragm or condom with spermicidal gel or foam); for two months
             prior to study enrollment or a vasectomized partner. All female subjects of child
             bearing potential must have undergone an in-office urine pregnancy test, with a
             negative result, prior to being randomized to receive study drug. In addition, women
             of childbearing potential must have agreed to a have urine pregnancy test at Day 42
             and at the end of the study (Day 84). Females not of childbearing potential due to
             menopause must have been postmenopausal for at least one year. Male subjects must be
             willing to not attempt to conceive a child during the participation in the study.
             Females utilizing oral contraception must be willing to utilize an appropriate
             secondary form of contraception during the study.

          -  Subjects who use the same brand of soap, make-up, hair products, or shaving
             lotion/foam/cream/gel for a period of at least four weeks prior to the Baseline Visit
             and agree not to change these product brand/types during the study, with the exception
             of using the study approved cleanser and moisturizer with sunscreen provided by the
             sponsor.

          -  Male subjects who are willing to shave, if applicable, at approximately the same time
             every day.

          -  Subjects who are willing to refrain from sunbathing, using sun tanning booths/beds, or
             excessive exposure to the sun for the duration of the study.

        Exclusion Criteria:

          -  Presence of any skin condition on the face that would interfere with the diagnosis or
             assessment of rosacea as determined by the Investigator.

          -  Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere
             with diagnosis or assessment of rosacea. Patients also must not grow excess facial
             hair during the study (i.e. they need to be free of excess facial hair for follow-up
             visits).

          -  History of hypersensitivity or allergy to minocycline, any other tetracycline or any
             other component of the formulation, or known reactions to cleansers, including Ponds
             Cold Cream, and moisturizer with sunscreen.

          -  Subjects using, or planning use of concomitant treatments within 30 days prior to
             Baseline visit (e.g., facial or chemical peels, dermal fillers, acne surgery,
             intralesional steroids, spironolactone, debridement, cryotherapy, dermabrasion, X-ray,
             IPL, laser therapy or UV therapy).

          -  Use within 6 months prior to baseline of oral retinoids (e.g. isotretinoin, acitretin)
             or therapeutic vitamin A supplements of greater than 10,000 International Units/day
             (multivitamins are allowed).

          -  Subjects using estrogens or progestin agents (e.g., Gynogen, Valergen, Depo-Testadiol,
             Depogen, birth control pills), for less than 2 months prior to the Baseline Visit.
             (Subjects using estrogens for 2 months or more are not excluded unless the subject
             expected to change dose, drug, or discontinue estrogen use during the study).

          -  Use within 2 month prior to the Baseline Visit of 1) topical retinoids to the face, 2)
             systemic antibiotics known to have an impact on the severity of facial rosacea (e.g.,
             containing tetracycline and its derivatives, erythromycin and its derivatives,
             sulfamethoxazole, or trimethoprim, metronidazole), or 3) systemic corticosteroids.

          -  Use within 2 months prior to the Baseline Visit of 1) topical corticosteroids, 2)
             topical antibiotics or 3) topical medications for rosacea (e.g., metronidazole,
             azelaic acid, erythromycin, ivermectin, sulfur based topical products).

          -  Subjects with rhinophyma, dense telangiectasia, or plaque-like facial edema, more than
             5 nodules or sinus tracts.

          -  Ocular rosacea (e.g., conjunctivitis, blepharitis, or keratitis) of sufficient
             severity to require topical or systemic antibiotics.

          -  Subjects with underlying diseases or other dermatological conditions, such as; atopic
             dermatitis, perioral dermatitis, or seborrheic dermatitis, which required the use of
             interfering topical or systemic therapy or may have interfered with the rosacea
             diagnosis.

          -  Subjects using an investigational drug or participating in an investigational study
             within 30 days of the Baseline Visit. Use of an investigational drug and/or
             participation in another investigational study prohibited during this study.

          -  Subjects who currently abuse alcohol or drugs or who have a history of chronic alcohol
             or drug abuse with in the past year.

          -  Medical history of immunodeficiency or other significant ongoing medical condition or
             disease as determined by the investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sunil S Dhawan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Dermatology Clinical Research, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>George Magrath, MD</last_name>
    <phone>(609) 918-2600</phone>
    <email>gmagrath@hovione.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Site - 15</name>
      <address>
        <city>Bryant</city>
        <state>Arkansas</state>
        <zip>72022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 20</name>
      <address>
        <city>Rogers</city>
        <state>Arkansas</state>
        <zip>72758</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology Clinical Research, Inc.</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sunil S Dhawan, MD</last_name>
      <phone>510-797-4111</phone>
      <phone_ext>5</phone_ext>
      <email>sdhaw@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 19</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 5</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33624</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 16</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 22</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02116</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 23</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 14</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 6</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 12</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 21</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 13</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 2</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 4</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 17</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 11</name>
      <address>
        <city>Fort Washington</city>
        <state>Pennsylvania</state>
        <zip>19034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 8</name>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 7</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 18</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 3</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 9</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Site - 10</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2017</study_first_submitted>
  <study_first_submitted_qc>August 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2017</study_first_posted>
  <last_update_submitted>February 23, 2018</last_update_submitted>
  <last_update_submitted_qc>February 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Minocycline</keyword>
  <keyword>Topical</keyword>
  <keyword>Tetracycline</keyword>
  <keyword>Doxycycline</keyword>
  <keyword>Rosacea</keyword>
  <keyword>Skin Disease</keyword>
  <keyword>Anti-Bacterial Agent</keyword>
  <keyword>Anti-Inflammatory Agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

